NO20075155L - Fremgangsmater for behandling av medikamentmisbruk og -avhengighet. - Google Patents
Fremgangsmater for behandling av medikamentmisbruk og -avhengighet.Info
- Publication number
- NO20075155L NO20075155L NO20075155A NO20075155A NO20075155L NO 20075155 L NO20075155 L NO 20075155L NO 20075155 A NO20075155 A NO 20075155A NO 20075155 A NO20075155 A NO 20075155A NO 20075155 L NO20075155 L NO 20075155L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- addiction
- compositions
- treating
- drug abuse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det beskrives fremgangsmåter og blandinger for behandling og lindring av symptomer og sykdom forbundet med indikasjoner forårsaket av en fysiologisk drivkraft til å lindre en følelse av angst. Nærmere bestemt beskrives fremgangsmåter og blandinger for behandling og lindring av symptomer forbundet med stoffmisbruk og abstinens. Det beskrives fremgangsmåter og blandinger for behandling og lindring av symptomer forbundet med addiksjon til antidepressiva, opiater, nikotin eller marihuana. Etter en fremgangsmåte behandles en pasient med en blanding som direkte eller indirekte modulerer GABAA ved å modulere ekspresjonen av GABAA reseptor (4-subenheten.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66903305P | 2005-04-07 | 2005-04-07 | |
US72901305P | 2005-10-21 | 2005-10-21 | |
US72897905P | 2005-10-21 | 2005-10-21 | |
PCT/US2006/013099 WO2006110557A2 (en) | 2005-04-07 | 2006-04-07 | Methods for the treatment of substance abuse and dependence |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20075155L true NO20075155L (no) | 2008-01-07 |
Family
ID=37087555
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20075161A NO20075161L (no) | 2005-04-07 | 2007-10-10 | Fremgangsmate for behandling av angstrelaterte lidelser |
NO20075155A NO20075155L (no) | 2005-04-07 | 2007-10-10 | Fremgangsmater for behandling av medikamentmisbruk og -avhengighet. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20075161A NO20075161L (no) | 2005-04-07 | 2007-10-10 | Fremgangsmate for behandling av angstrelaterte lidelser |
Country Status (12)
Country | Link |
---|---|
US (3) | US20080207601A1 (no) |
EP (3) | EP1868593A2 (no) |
JP (3) | JP2008538748A (no) |
KR (2) | KR20080004580A (no) |
AU (3) | AU2006235318A1 (no) |
BR (2) | BRPI0609744A2 (no) |
CA (3) | CA2604887A1 (no) |
CR (2) | CR9410A (no) |
IL (2) | IL186450A0 (no) |
MX (2) | MX2007012353A (no) |
NO (2) | NO20075161L (no) |
WO (3) | WO2006110642A2 (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192271A1 (en) | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
WO2006110642A2 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
US20090269795A1 (en) * | 2007-03-09 | 2009-10-29 | The Research Foundation Of State University Of New York | Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability |
US8586634B2 (en) | 2007-06-15 | 2013-11-19 | University Of Florida Research Foundation, Inc. | Therapeutic compounds |
CA2707980C (en) | 2007-12-17 | 2015-05-12 | Labopharm Inc. | Misuse preventative, controlled release formulation |
ITRM20080436A1 (it) * | 2008-08-06 | 2010-02-07 | Francesco Marrosu | Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita' |
TWI541246B (zh) | 2008-12-08 | 2016-07-11 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
JP5667575B2 (ja) | 2008-12-16 | 2015-02-12 | パラディン ラブス インコーポレーテッド | 誤用を防止する放出制御製剤 |
WO2010094074A1 (en) * | 2009-02-20 | 2010-08-26 | Palmaya Pty Ltd | Pharmaceutical preparation and delivery system |
US20120295893A1 (en) * | 2009-12-14 | 2012-11-22 | Coeruleus Ltd. | Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs |
CA2785056A1 (en) | 2009-12-22 | 2011-07-21 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
WO2012006683A1 (en) * | 2010-07-16 | 2012-01-19 | Controlled Release Technologies Pty Ltd | Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists |
US8968722B2 (en) * | 2010-12-29 | 2015-03-03 | Mead Johnson Nutrition Company | Milk-based nutritional compositions containing lactoferrin and uses thereof |
WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
US20150018327A1 (en) | 2012-01-23 | 2015-01-15 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
KR102305359B1 (ko) * | 2012-08-21 | 2021-09-24 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
EP3160969B1 (en) * | 2014-06-26 | 2023-09-13 | The Johns Hopkins University | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system |
IL300422A (en) | 2016-03-08 | 2023-04-01 | Sage Therapeutics Inc | Neuroactive steroids, preparations and their uses |
US20180050005A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
CA3046128A1 (en) * | 2017-01-09 | 2018-07-12 | Asarina Pharma Ab | Injectable suspensions |
KR20200072445A (ko) * | 2017-03-28 | 2020-06-22 | 엘디엔 파마 리미티드 | 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제 |
GB201704909D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
KR101898814B1 (ko) | 2017-09-07 | 2018-09-13 | 백창목 | 도어 개폐용 도어록 |
WO2019055942A1 (en) * | 2017-09-18 | 2019-03-21 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE |
CA3076193A1 (en) * | 2017-09-18 | 2019-03-21 | SEN-JAM Pharmaceutical LLC | Methods and compositions to inhibit symptoms associated with opioid withdrawal |
US10966988B2 (en) * | 2017-09-20 | 2021-04-06 | Calista Capital, Llc | Method for smoking cessation |
EP3482751A1 (en) * | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
JP2021519799A (ja) * | 2018-04-05 | 2021-08-12 | アサリナ ファーマ エーピーエス | 物質離脱障害を治療するためのgaba−aアンタゴニスト |
EP3761979A4 (en) * | 2018-04-06 | 2021-06-30 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT SUBSTANCE ABUSE |
US10765666B2 (en) | 2018-09-20 | 2020-09-08 | Ovid Therapeutics Inc | Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering |
WO2020181340A1 (en) * | 2019-03-14 | 2020-09-17 | Palmaya Pty Ltd | Treatment of inflammatory diseases of the central nervous system |
US11559502B2 (en) * | 2019-08-26 | 2023-01-24 | Period Pill Bv | Treatment of menstrual cycle-induced symptoms |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034087A (en) * | 1973-12-17 | 1977-07-05 | The Regents Of The University Of Michigan | Pharmaceutical composition and process of treatment |
US4595684A (en) * | 1985-08-16 | 1986-06-17 | Ciba-Geigy Corporation | Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof |
US5175155A (en) * | 1991-10-07 | 1992-12-29 | Sterling Winthrop Inc. | Win 49596-finasteride method of use and compositions |
DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
FR2719843B1 (fr) * | 1994-05-10 | 1996-06-07 | Synthelabo | Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique. |
US5521181A (en) * | 1995-01-27 | 1996-05-28 | Abbott Laboratories | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
IT1274481B (it) * | 1995-05-12 | 1997-07-17 | Indena Spa | Composizioni farmaceutiche per il trattamento della alcol-dipendenza |
WO1999010003A1 (en) * | 1997-08-28 | 1999-03-04 | Janus Pharmaceuticals, Inc. | Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition |
US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
AU4100699A (en) | 1998-05-28 | 1999-12-13 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
EP1212051A4 (en) * | 1999-08-27 | 2004-03-31 | Merck & Co Inc | METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN |
AU2002226427B2 (en) | 2001-01-17 | 2006-11-16 | Hythiam, Inc. | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
US20020173495A1 (en) * | 2000-08-24 | 2002-11-21 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
IL157144A0 (en) | 2001-02-15 | 2004-02-08 | Hythiam Inc | Use of flumazenil to produce a medicament for the treatment of cocaine dependency |
GB0311859D0 (en) * | 2003-05-22 | 2003-06-25 | Merck Sharp & Dohme | Therapeutic agents |
ES2515092T3 (es) * | 2003-12-11 | 2014-10-29 | Sunovion Pharmaceuticals Inc. | Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión |
WO2006110642A2 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
-
2006
- 2006-04-06 WO PCT/US2006/013296 patent/WO2006110642A2/en active Application Filing
- 2006-04-06 JP JP2008505625A patent/JP2008538748A/ja not_active Withdrawn
- 2006-04-06 CA CA002604887A patent/CA2604887A1/en not_active Abandoned
- 2006-04-06 US US11/910,988 patent/US20080207601A1/en not_active Abandoned
- 2006-04-06 EP EP06749649A patent/EP1868593A2/en not_active Withdrawn
- 2006-04-06 AU AU2006235318A patent/AU2006235318A1/en not_active Abandoned
- 2006-04-07 KR KR1020077025773A patent/KR20080004580A/ko not_active Application Discontinuation
- 2006-04-07 MX MX2007012353A patent/MX2007012353A/es not_active Application Discontinuation
- 2006-04-07 KR KR1020077025774A patent/KR20080004581A/ko not_active Application Discontinuation
- 2006-04-07 WO PCT/US2006/013099 patent/WO2006110557A2/en active Application Filing
- 2006-04-07 CA CA002603533A patent/CA2603533A1/en not_active Abandoned
- 2006-04-07 CA CA002603519A patent/CA2603519A1/en not_active Abandoned
- 2006-04-07 WO PCT/US2006/013152 patent/WO2006110580A2/en active Application Filing
- 2006-04-07 AU AU2006235257A patent/AU2006235257B2/en not_active Ceased
- 2006-04-07 JP JP2008505580A patent/JP2008535850A/ja active Pending
- 2006-04-07 AU AU2006235234A patent/AU2006235234A1/en not_active Abandoned
- 2006-04-07 BR BRPI0609744-8A patent/BRPI0609744A2/pt not_active Application Discontinuation
- 2006-04-07 MX MX2007012355A patent/MX2007012355A/es not_active Application Discontinuation
- 2006-04-07 EP EP06740761A patent/EP1868432A4/en not_active Ceased
- 2006-04-07 US US11/910,967 patent/US8012958B2/en not_active Expired - Fee Related
- 2006-04-07 US US11/910,966 patent/US20080255097A1/en not_active Abandoned
- 2006-04-07 EP EP06749539A patent/EP1901727A4/en not_active Withdrawn
- 2006-04-07 BR BRPI0610693A patent/BRPI0610693A2/pt not_active IP Right Cessation
- 2006-04-07 JP JP2008505599A patent/JP2008535852A/ja active Pending
-
2007
- 2007-10-02 CR CR9410A patent/CR9410A/es unknown
- 2007-10-03 CR CR9413A patent/CR9413A/es not_active Application Discontinuation
- 2007-10-07 IL IL186450A patent/IL186450A0/en unknown
- 2007-10-07 IL IL186447A patent/IL186447A0/en unknown
- 2007-10-10 NO NO20075161A patent/NO20075161L/no not_active Application Discontinuation
- 2007-10-10 NO NO20075155A patent/NO20075155L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20075155L (no) | Fremgangsmater for behandling av medikamentmisbruk og -avhengighet. | |
Kasper et al. | Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action | |
Coelho‐de‐Souza et al. | Essential oil of Croton zehntneri and its major constituent anethole display gastroprotective effect by increasing the surface mucous layer | |
WO2006023703A3 (en) | Method for treating sleep related breathing disorders | |
BRPI0518011A (pt) | uso de tetraidrocanabidivarina, métodos para o tratamento de uma doença ou condição e para cosmeticamente beneficiar a perda de peso, e, uso de um antagonista do receptor de canabinóide neutro | |
BRPI0513840A (pt) | método para controle de obesidade em um paciente mamìfero necessitado de um tal tratamento, método para tratamento de obesidade em um paciente humano diabético e sendo tratado com uma droga receitada para diabetes, método para tratamento de diabetes mellitus em um paciente mamìfero necessitado de um tal tratamento para controle da diabetes mellitus, método para tratamento ou controle de hiperglicemia em um paciente mamìfero necessitado de um tal tratamento, composição para uso no tratamento de obesidade, diabetes, ou hiperglicemia como doença, método para tratamento ou controle de distúrbios lipìdicos, hiperlipidemia, ou baixo nìvel de hdl em um paciente mamìfero necessitado do mesmo, método para tratamento ou controle de hipercolesterolemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de hipergligeridemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de dislipidemia e/ou baixo nìvel de hdl colesterol em um paciente mamìfero necessitado de um tal tratamento, e método para tratamento de arteriosclerose em um paciente mamìfero necessitado de um tal tratamento | |
WO2006054057A3 (en) | New use for cannabinoid | |
NO20074117L (no) | Fremgangsmater og sammensetninger for a behandle diabetes, metabolske sykdommer og tilstander | |
NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
NO20084567L (no) | Polymorfe former av (2S) - (4E) -N-metyl-5-(3-isopropoksypyridin)yl]-4-penten-2-amin for behandling av sykdommer i sentralnervesystemet | |
Ashamalla et al. | Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy | |
BR0011891A (pt) | Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso | |
CR10627A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
NO20055129L (no) | Fenylsubstituerte karboksylsyrer | |
WO2004052284A3 (en) | Treatment of diabetes | |
NO20050204L (no) | Kombinasjoner av legemidler for behandling av neoplasmer | |
MX2011006224A (es) | Composicion que comprende isoflavonas. | |
Makhlouf et al. | Depression and erectile dysfunction | |
Liu et al. | Acupuncture at both ST25 and ST37 improves the pain threshold of chronic visceral hypersensitivity rats | |
WO2007070637A3 (en) | Method of treating open wounds using hypochlorous acid | |
WO2008036448A3 (en) | Composition and method of treating a sore throat | |
Bai et al. | Suxiao jiuxin pill induces potent relaxation and inhibition on contraction in human artery and the mechanism | |
CR8850A (es) | Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales | |
BRPI0606833A2 (pt) | uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico | |
Soltanzadeh et al. | Effects of acupressure on nausea and vomiting after gynecological laparoscopy surgery for infertility investigations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |